BridgeBio Pharma (NASDAQ:BBIO) Hits New 52-Week High – Should You Buy?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) shares reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $84.06 and last traded at $79.8380, with a volume of 788746 shares changing hands. The stock had previously closed at $73.33.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: PROPEL 3 Phase‑3 topline: infigratinib met the primary endpoint (annualized height velocity) with a meaningful treatment difference vs. placebo, reported favorable safety, and BridgeBio plans NDA/MAA submissions in H2 2026 — a major de‑risking and commercialization step that drove earlier buying interest. Read More.
• Positive Sentiment: Analyst upgrades/target bumps: Wells Fargo raised its target to $98 (overweight) and Oppenheimer lifted its target to $83 (outperform). Those upgrades reinforced the commercial/regulatory narrative and supported the rally earlier in the week. Read More. Read More.
• Positive Sentiment: Competitive impact: BridgeBio’s positive data pressured rival programs (reports note BioMarin and Ascendis shares fell), suggesting BridgeBio may gain market share if approvals follow. Read More.
• Neutral Sentiment: Short‑interest reporting shows zero shares (likely a data or reporting glitch) and is not informative for positioning; ignore that metric until corrected by exchanges/data vendors.
• Negative Sentiment: Insider selling: CEO Neil Kumar sold 40,000 shares on Feb 10 (~$2.88M), part of a pattern of recent sales. That can prompt profit‑taking or investor concern about insider conviction despite large remaining holdings. Read More.
• Negative Sentiment: Near‑term financials remain a risk: Zacks flagged likely negative earnings in the upcoming report, keeping short‑term P&L and cash‑burn concerns on the table despite the clinical win. Read More.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BBIO. Morgan Stanley started coverage on BridgeBio Pharma in a report on Tuesday, January 6th. They set an “overweight” rating and a $96.00 target price for the company. Cantor Fitzgerald raised their price target on shares of BridgeBio Pharma from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Pharma in a research note on Wednesday, January 21st. Piper Sandler boosted their price objective on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Finally, Oppenheimer raised their target price on shares of BridgeBio Pharma from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Friday. Twenty-two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $81.55.

BridgeBio Pharma Stock Performance

The stock has a market capitalization of $14.50 billion, a P/E ratio of -18.00 and a beta of 1.13. The firm’s fifty day simple moving average is $75.60 and its 200 day simple moving average is $63.08.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, CAO Maricel Apuli sold 2,000 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $74.26, for a total transaction of $148,520.00. Following the completion of the sale, the chief accounting officer directly owned 130,297 shares in the company, valued at $9,675,855.22. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Randal W. Scott sold 10,000 shares of the business’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $66.65, for a total value of $666,500.00. Following the transaction, the director directly owned 11,589 shares of the company’s stock, valued at $772,406.85. This trade represents a 46.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 300,700 shares of company stock valued at $21,034,671. 18.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Norges Bank bought a new stake in shares of BridgeBio Pharma during the 2nd quarter valued at approximately $84,488,000. Invesco Ltd. lifted its stake in BridgeBio Pharma by 40.3% in the 3rd quarter. Invesco Ltd. now owns 3,928,657 shares of the company’s stock valued at $204,054,000 after purchasing an additional 1,127,592 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in BridgeBio Pharma by 14,211.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 994,220 shares of the company’s stock valued at $77,783,000 after buying an additional 987,273 shares in the last quarter. Polar Capital Holdings Plc bought a new stake in shares of BridgeBio Pharma during the third quarter worth $50,956,000. Finally, Wellington Management Group LLP increased its holdings in shares of BridgeBio Pharma by 1,698.5% during the third quarter. Wellington Management Group LLP now owns 1,019,194 shares of the company’s stock worth $52,937,000 after buying an additional 962,525 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.